About Shire PLC (NASDAQ:SHPG)
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).
Industry, Sector and Symbol:
- Industry: Pharmaceuticals
- Sub-Industry: N/A
- Sector: Healthcare
- Symbol: NASDAQ:SHPG
- CUSIP: N/A
- Web: www.shire.com
- Debt-to-Equity Ratio: 0.55%
- Current Ratio: 0.98%
- Quick Ratio: 0.52%
Sales & Book Value:
- Trailing P/E Ratio: 10.14
- Forward P/E Ratio: 9.42
- P/E Growth: 0.82
- Annual Sales: $11.3966 billion
- Price / Sales: 3.73
- Cash Flow: $15.71 per share
- Price / Cash: 9.00
- Book Value: $95.20 per share
- Price / Book: 1.48
- Annual Dividend: $0.92
- Dividend Yield: 0.6%
- Trailing EPS: $5.31
- Net Income: $327.4 million
- Net Margins: 10.95%
- Return on Equity: 14.41%
- Return on Assets: 6.60%
- Employees: 23,906
- Outstanding Shares: 300,430,000
Frequently Asked Questions for Shire PLC (NASDAQ:SHPG)
What is Shire PLC's stock symbol?
Shire PLC trades on the NASDAQ under the ticker symbol "SHPG."
How often does Shire PLC pay dividends? What is the dividend yield for Shire PLC?
Shire PLC declared a semiannual dividend on Friday, August 11th. Investors of record on Friday, September 8th will be given a dividend of $0.1527 per share on Friday, October 20th. This represents a yield of 0.21%. The ex-dividend date of this dividend is Thursday, September 7th. View Shire PLC's Dividend History.
How were Shire PLC's earnings last quarter?
Shire PLC (NASDAQ:SHPG) announced its quarterly earnings results on Friday, October, 27th. The biopharmaceutical company reported $3.81 earnings per share for the quarter, topping analysts' consensus estimates of $3.64 by $0.17. The biopharmaceutical company earned $3.70 billion during the quarter. Shire PLC had a net margin of 10.95% and a return on equity of 14.41%. The company's revenue for the quarter was up 7.1% on a year-over-year basis. During the same period last year, the firm earned $3.17 EPS. View Shire PLC's Earnings History.
When will Shire PLC make its next earnings announcement?
What guidance has Shire PLC issued on next quarter's earnings?
Shire PLC issued an update on its FY17 earnings guidance on Friday, October, 27th. The company provided EPS guidance of $14.80-15.20 for the period, compared to the Thomson Reuters consensus estimate of $14.92. The company issued revenue guidance of $14.9-15.3 billion, compared to the consensus revenue estimate of $14.97 billion.
Where is Shire PLC's stock going? Where will Shire PLC's stock price be in 2017?
15 brokers have issued 12-month price objectives for Shire PLC's stock. Their forecasts range from $160.00 to $245.00. On average, they anticipate Shire PLC's share price to reach $212.18 in the next year. View Analyst Ratings for Shire PLC.
What are Wall Street analysts saying about Shire PLC stock?
Here are some recent quotes from research analysts about Shire PLC stock:
- 1. According to Zacks Investment Research, "The approval of Mydayis is likely to boost Shire’s ADHD segment dominance while strong performance of Vyvanse, Cinryze and Elaprase will continue to drive Shire’s top line. The label expansion of Cinryze in paediatrics and conditional approval of Natpara in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology portfolio, acquiring roughly 23% of the total market by the end of Jun 2017. However, the adult ADHD space is one of the largest and fastest growing segments of the market but is highly genericized. Moreover, shares have underperformed the industry so far this year. Estimates have risen ahead of Q3 earnings. The company has a mixed record of earnings surprises in recent quarters." (10/27/2017)
- 2. Cantor Fitzgerald analysts commented, "This morning, SHPG announced that the Marketing Authorization Application (MAA) for Lifitegrast has been validated by the UK as the Reference Member State involved in the Decentralized Procedure (DCP)." (8/15/2017)
- 3. Jefferies Group LLC analysts commented, "SHPG posted strong 4Q16 revs ($3.8B vs $3.7B JEF) and EPS ($3.37 vs $3.26 JEF) as nearly all core franchises performed well. In particular, GI and Orphan Diseases showed strength. As for legacy BXLT, Immunoglobulins and Hemophilia performed well while Inhibitors lagged. We like the setup for 2017. If mgt executes on core brands, the Xiidra launch, and the BXLT integration, we could envision share price outperformance, augmented by significant deleveraging." (2/17/2017)
Who are some of Shire PLC's key competitors?
Some companies that are related to Shire PLC include GlaxoSmithKline PLC (GSK), Astrazeneca PLC (AZN), Celgene Corporation (CELG), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY), Valeant Pharmaceuticals International (VRX), Patheon N.V. (PTHN), Catalent (CTLT), Taro Pharmaceutical Industries (TARO), Akorn (AKRX), BTG plc (BTG), Opko Health (OPK), Hikma Pharmaceuticals PLC (HIK), Horizon Pharma PLC (HZNP) and Amicus Therapeutics (FOLD).
Who are Shire PLC's key executives?
Shire PLC's management team includes the folowing people:
- Flemming Ornskov M.D., Chief Executive Officer, Executive Director (Age 59)
- Jeffrey Poulton, Chief Financial Officer, Executive Director (Age 49)
- Joanne Cordeiro, Chief Human Resource Officer
- Gisele Dion, Chief Accounting Officer, Corporate Controller (Age 51)
- William Mordan, General Counsel, Company Secretary (Age 47)
- Perry Sternberg, Head - U.S. Commercial (Age 48)
- Kim Stratton, Head - International Commercial (Age 54)
- Philip J. Vickers, Head - Research and Development (Age 56)
- Matthew Walker, Head - Technical Operations (Age 53)
- Susan Saltzbart Kilsby, Independent Non-Executive Chairman of the Board (Age 58)
Who owns Shire PLC stock?
Shire PLC's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Harding Loevner LP (42.47%), Janus Henderson Group PLC (0.58%), Ameriprise Financial Inc. (0.53%), Boston Partners (0.49%), Third Point LLC (0.40%) and Jennison Associates LLC (0.26%). View Institutional Ownership Trends for Shire PLC.
Who sold Shire PLC stock? Who is selling Shire PLC stock?
Shire PLC's stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Allianz Asset Management GmbH, Sei Investments Co., Dividend Assets Capital LLC, Rockefeller Financial Services Inc., Third Avenue Management LLC, Zweig DiMenna Associates LLC and Point72 Asset Management L.P.. View Insider Buying and Selling for Shire PLC.
Who bought Shire PLC stock? Who is buying Shire PLC stock?
Shire PLC's stock was purchased by a variety of institutional investors in the last quarter, including Harding Loevner LP, Third Point LLC, Sterling Capital Management LLC, Janus Henderson Group PLC, Seatown Holdings Pte. Ltd., Van ECK Associates Corp, Boston Partners and GMT Capital Corp. View Insider Buying and Selling for Shire PLC.
How do I buy Shire PLC stock?
Shares of Shire PLC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Shire PLC's stock price today?
One share of Shire PLC stock can currently be purchased for approximately $147.37.
How big of a company is Shire PLC?
Shire PLC has a market capitalization of $44.1 billion and generates $11.3966 billion in revenue each year. The biopharmaceutical company earns $327.4 million in net income (profit) each year or $5.31 on an earnings per share basis. Shire PLC employs 23,906 workers across the globe.
How can I contact Shire PLC?
Shire PLC's mailing address is Miesian Plaza 50-58 Baggot Street Lower, Block 2, DUBLIN, D02 HW68, Ireland. The biopharmaceutical company can be reached via phone at +353-1-6096000 or via email at [email protected]
MarketBeat Community Rating for Shire PLC (NASDAQ SHPG)MarketBeat's community ratings are surveys of what our community members think about Shire PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Shire PLC (NASDAQ:SHPG) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 5 Hold Ratings, 10 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 2.67)|
|Consensus Price Target: ||$212.18 (50.09% upside)|
Consensus Price Target History for Shire PLC (NASDAQ:SHPG)
Analysts' Ratings History for Shire PLC (NASDAQ:SHPG)
(Data available from 11/20/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/16/2017||Royal Bank Of Canada||Reiterated Rating||Buy||N/A|
|11/16/2017||Cantor Fitzgerald||Set Price Target||Buy||$222.00||N/A|
|11/14/2017||Liberum Capital||Upgrade||Hold -> Buy||N/A|
|10/30/2017||FBR & Co||Reiterated Rating||Buy||$201.00||N/A|
|10/29/2017||Cowen and Company||Set Price Target||Buy||$225.00||N/A|
|10/27/2017||Piper Jaffray Companies||Reiterated Rating||Hold||$160.00||N/A|
|10/8/2017||Stifel Nicolaus||Reiterated Rating||Buy||$245.00||N/A|
|8/16/2017||Evercore ISI||Initiated Coverage||Outperform -> Outperform||$196.00||Medium|
|8/11/2017||Barclays PLC||Downgrade||Overweight -> Equal Weight||Low|
|8/9/2017||Jefferies Group LLC||Reiterated Rating||Hold||$216.00 -> $206.00||Low|
|7/17/2017||BTIG Research||Reiterated Rating||Buy||$242.00||Low|
|7/13/2017||Sanford C. Bernstein||Reiterated Rating||Market Perform||$210.00||Low|
|4/17/2017||Goldman Sachs Group, Inc. (The)||Boost Price Target||Overweight||$202.00 -> $214.00||Low|
|12/2/2016||Societe Generale||Initiated Coverage||Buy||N/A|
|11/14/2016||Leerink Swann||Set Price Target||Buy||$198.00||N/A|
|11/7/2016||J P Morgan Chase & Co||Reiterated Rating||Overweight||N/A|
|11/3/2016||Citigroup Inc.||Reiterated Rating||Buy||N/A|
|11/2/2016||Deutsche Bank AG||Reiterated Rating||Buy||N/A|
|10/23/2016||BNP Paribas||Reiterated Rating||Buy||N/A|
|10/8/2016||Shore Capital||Reiterated Rating||Buy||N/A|
|6/3/2016||Morgan Stanley||Reiterated Rating||Overweight||N/A|
|5/23/2016||Bryan, Garnier & Co||Initiated Coverage||Buy||N/A|
|3/30/2016||Bank of America Corporation||Reiterated Rating||Buy||N/A|
|2/13/2016||Northland Securities||Reiterated Rating||Buy||N/A|
|2/8/2016||Susquehanna Bancshares Inc||Lower Price Target||Positive||$280.00 -> $220.00||N/A|
|1/18/2016||Credit Suisse Group||Upgrade||Buy||N/A|
Earnings History and Estimates Chart for Shire PLC (NASDAQ:SHPG)
Earnings History by Quarter for Shire PLC (NASDAQ SHPG)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/15/2018|| || || || || || || || |
|5/2/2017||Q1 17||$3.22||$3.63||$3.57 billion||View||Listen|
|2/16/2017||Q416||$3.24||$3.37||$3.78 billion||$3.81 billion||View||N/A|
|11/1/2016||Q316||$3.21||$3.17||$3.57 billion||$3.45 billion||View||N/A|
|8/2/2016||Q216||$3.03||$3.38||$2.28 billion||$2.43 million||View||N/A|
|4/29/2016||Q1||$3.05||$3.19||$1.71 billion||$1.71 billion||View||Listen|
|2/11/2016||Q415||$2.89||$2.97||$1.69 million||$1.72 billion||View||Listen|
|10/23/2015||Q315||$2.87||$3.24||$1.63 billion||$1.58 billion||View||Listen|
|7/23/2015||Q215||$2.81||$2.63||$1.59 billion||$1.56 billion||View||Listen|
|4/30/2015||Q115||$2.56||$2.84||$1.47 billion||$1.49 billion||View||N/A|
|2/12/2015||Q115||$2.68||$2.63||$1.53 billion||$1.58 billion||View||N/A|
|10/24/2014||Q314||$2.47||$2.93||$1.46 billion||$1.55 billion||View||Listen|
|7/18/2014||Q214||$2.45||$2.67||$1.45 billion||$1.50 billion||View||N/A|
|5/1/2014||Q114||$2.22||$2.36||$1.38 billion||$1.35 billion||View||N/A|
|2/13/2014||Q413||$2.02||$2.26||$1.28 billion||$1.33 billion||View||N/A|
|10/24/2013||Q213||$1.65||$1.77||$1.23 billion||$1.24 billion||View||N/A|
|7/25/2013||$1.60||$1.79||$1.21 billion||$1.28 billion||View||N/A|
|5/2/2013||Q113||$1.56||$1.63||$1.21 billion||$1.16 billion||View||N/A|
|2/14/2013||Q412||$1.58||$1.58||$1.20 billion||$1.20 billion||View||N/A|
Earnings Estimates for Shire PLC (NASDAQ:SHPG)
2017 EPS Consensus Estimate: $14.66
2018 EPS Consensus Estimate: $16.52
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Current Dividend Information for Shire PLC (NASDAQ:SHPG)
|Most Recent Dividend:||10/20/2017|
|Payout Ratio:||17.33% (Trailing 12 Months of Earnings) |
6.13% (Based on This Year's Estimates)
5.74% (Based on Next Year's Estimates)
Dividend History by Quarter for Shire PLC (NASDAQ SHPG)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading History for Shire PLC (NASDAQ SHPG)
No insider trades for this company have been tracked by MarketBeat.com
Latest Headlines for Shire PLC (NASDAQ SHPG)
|Shire plc : Directorate change - GlobeNewswire (press release)|
globenewswire.com - November 20 at 9:54 AM
|Ultragenyx's rhGUS Gets FDA Nod for Rare Genetic Disease|
www.nasdaq.com - November 17 at 7:06 PM
|Cantor Fitzgerald Reiterates "$222.00" Price Target for Shire PLC (SHPG)|
www.americanbankingnews.com - November 16 at 3:28 PM
|Shire PLC (SHPG) Stock Rating Reaffirmed by Royal Bank Of Canada|
www.americanbankingnews.com - November 16 at 3:28 PM
|Polygon Management Ltd. Buys Shire PLC, IAC/InterActiveCorp, Ambac Financial Group Inc, Sells ... - Nasdaq|
www.nasdaq.com - November 15 at 3:42 PM
|Shire PLC (SHPG) Lifted to Buy at Liberum Capital|
www.americanbankingnews.com - November 14 at 8:28 PM
|Shire: CHMP Recommends Hemophilia A Drug ADYNOVI For EU Marketing Authorization|
www.nasdaq.com - November 14 at 7:53 AM
|European advisory group backs Shire's long-acting Factor VIII for hemophilia A|
seekingalpha.com - November 14 at 7:53 AM
|CHMP recommends EU marketing authorization for ADYNOVI® for adults and adolescents with Hemophilia A|
finance.yahoo.com - November 14 at 7:53 AM
|Analytics for Industry Group Rank Make Shire (SHPG) a Sell|
investorplace.com - November 13 at 4:58 PM
|Dan Loeb Soars High in Alibaba - Nasdaq|
www.nasdaq.com - November 11 at 1:34 PM
|Shire presentations at ASH 2017 highlight commitment to furthering research and innovation in Hematology and Oncology|
feeds.benzinga.com - November 10 at 7:56 AM
|FY2019 EPS Estimates for Shire PLC (SHPG) Reduced by SunTrust Banks|
www.americanbankingnews.com - November 9 at 3:40 PM
|Shire PLC Forecasted to Post Q4 2017 Earnings of $3.80 Per Share (SHPG)|
www.americanbankingnews.com - November 8 at 1:14 PM
|$4.00 Billion in Sales Expected for Shire PLC (SHPG) This Quarter|
www.americanbankingnews.com - November 5 at 6:44 AM
|ETFs with exposure to Shire Plc : November 3, 2017|
finance.yahoo.com - November 4 at 2:50 PM
|Zacks: Analysts Anticipate Shire PLC (SHPG) to Announce $3.90 EPS|
www.americanbankingnews.com - November 3 at 7:34 PM
|Head-To-Head Comparison: Shire PLC (SHPG) vs. Impax Laboratories (IPXL)|
www.americanbankingnews.com - November 2 at 5:30 PM
|Xenetic Biosciences Enters Into Sublicense Agreement Related to its PolyXen™ Technology with Baxalta Inc., a Wholly-owned Subsidiary of Shire plc|
finance.yahoo.com - November 2 at 8:45 AM
|Earnings Review and Free Research Report: Eli Lilly’s Adjusted EPS Increased 19%|
finance.yahoo.com - November 2 at 8:44 AM
|Shire PLC (SHPG) Given Consensus Recommendation of "Buy" by Brokerages|
www.americanbankingnews.com - November 1 at 3:42 PM
|Q4 2017 EPS Estimates for Shire PLC Cut by William Blair (SHPG)|
www.americanbankingnews.com - November 1 at 11:31 AM
|FY2017 EPS Estimates for Shire PLC (SHPG) Cut by Cantor Fitzgerald|
www.americanbankingnews.com - November 1 at 8:54 AM
|Shire (SHPG) Q3 Earnings Beat, Immunology Franchise Strong - Nasdaq|
www.nasdaq.com - October 31 at 9:25 AM
|Shire (SHPG) Q3 Earnings Beat, Immunology Franchise Strong|
finance.yahoo.com - October 31 at 9:25 AM
|Analysts Issue Forecasts for Shire PLC's FY2017 Earnings (SHPG)|
www.americanbankingnews.com - October 31 at 6:48 AM
|Shire PLC to Post FY2017 Earnings of $15.10 Per Share, FBR & Co Forecasts (SHPG)|
www.americanbankingnews.com - October 31 at 6:48 AM
|Falling Earnings Visibility Keeps Shire (SHPG) a Sell|
investorplace.com - October 30 at 3:59 PM
|Fund manager, analysts make the case for this ‘loathed’ pharma stock|
finance.yahoo.com - October 30 at 7:05 AM
|Shire PLC (SHPG) Stock Rating Reaffirmed by Cantor Fitzgerald|
www.americanbankingnews.com - October 28 at 2:08 PM
|Shire PLC (SHPG) Posts Earnings Results, Beats Estimates By $0.15 EPS|
www.americanbankingnews.com - October 27 at 9:32 PM
|Zacks Investment Research Upgrades Shire PLC (SHPG) to Hold|
www.americanbankingnews.com - October 27 at 1:00 PM
|Shire PLC (SHPG) Releases FY17 Earnings Guidance|
www.americanbankingnews.com - October 27 at 8:56 AM
|Shire plc : 3rd Quarter Results|
feeds.benzinga.com - October 27 at 8:05 AM
|Shire Receives European Approval for Label Extension of FIRAZYR® (icatibant injection) for the Symptomatic Treatment of Acute HAE Attacks in Paediatric Patients|
feeds.benzinga.com - October 26 at 2:51 AM
|Shire Gets Orphan Drug Designation For Gene Therapy Candidate SHP654 - Nasdaq|
www.nasdaq.com - October 25 at 10:38 AM
|Shire (SHPG) a Sell on Falling Quant Score - Investorplace.com|
investorplace.com - October 25 at 10:38 AM
|Shire Receives Orphan Drug Designation for Gene Therapy Candidate SHP654 (BAX 888) for the Treatment of Hemophilia A|
feeds.benzinga.com - October 25 at 8:04 AM
|Shire to Present New Data to Help Advance Understanding of Rare Diseases|
www.nasdaq.com - October 24 at 9:57 AM
|ETFs with exposure to Shire Plc : October 23, 2017|
finance.yahoo.com - October 24 at 9:57 AM
|Shire PLC Expected to Post Q3 2017 Earnings of $3.70 Per Share (SHPG)|
www.americanbankingnews.com - October 23 at 1:30 AM
|Shire PLC (SHPG) Earns Buy Rating from Analysts at FBR & Co|
www.americanbankingnews.com - October 22 at 5:16 PM
|Financial Analysis: Shire PLC (SHPG) vs. Its Competitors|
www.americanbankingnews.com - October 21 at 4:34 PM
|Shire PLC (SHPG) Stock Rating Lowered by Zacks Investment Research|
www.americanbankingnews.com - October 20 at 12:32 PM
|Create the Soundtrack to Your Unique Day with "Compose Your Life"|
finance.yahoo.com - October 20 at 8:05 AM
|William Blair Analysts Boost Earnings Estimates for Shire PLC (SHPG)|
www.americanbankingnews.com - October 19 at 11:28 AM
|Generic Restasis Risk Metastasizes To Shire - Seeking Alpha|
seekingalpha.com - October 19 at 8:48 AM
|Q3 2017 EPS Estimates for Shire PLC (SHPG) Lifted by SunTrust Banks|
www.americanbankingnews.com - October 19 at 7:18 AM
|Shire PLC to Post FY2019 Earnings of $18.17 Per Share, William Blair Forecasts (SHPG)|
www.americanbankingnews.com - October 18 at 2:40 PM
|Analysts Issue Forecasts for Shire PLC's FY2018 Earnings (SHPG)|
www.americanbankingnews.com - October 18 at 1:10 PM
Financials are not available for this stock.
Shire PLC (NASDAQ SHPG) Chart for Monday, November, 20, 2017